Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3) : a multicentre phase III study with a doubleblind, randomised withdrawal phase

Pivonello, R., Fleseriu, M., Newell-Price, J. et al. (14 more authors) (2020) Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3) : a multicentre phase III study with a doubleblind, randomised withdrawal phase. The Lancet Diabetes & Endocrinology. ISSN 2213-8587

Abstract

Metadata

Authors/Creators:
  • Pivonello, R.
  • Fleseriu, M.
  • Newell-Price, J.
  • Bertagna, X.
  • Findling, J.
  • Shimatsu, A.
  • Gu, F.
  • Auchus, R.
  • Leelawattana, R.
  • Lee, E.J.
  • Kim, J.H.
  • Lacroix, A.
  • Laplanche, A.
  • O'Connell, P.
  • Tauchmanova, L.
  • Pedroncelli, A.M.
  • Biller, B.M.K.
Copyright, Publisher and Additional Information: © 2020 Elsevier. This is an author produced version of a paper subsequently published in The Lancet Diabetes and Endocrinology. Uploaded in accordance with the publisher's self-archiving policy. Article available under the terms of the CC-BY-NC-ND licence (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Dates:
  • Published (online): 27 July 2020
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Funding Information:
FunderGrant number
Sheffield Teaching Hospitals NHS Foundation TrustSTH18457
Depositing User: Symplectic Sheffield
Date Deposited: 04 Aug 2020 06:49
Last Modified: 04 Aug 2020 06:49
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/s2213-8587(20)30240-0

Download

Accepted Version


Embargoed until: 27 January 2021

Filename: LINC3 primary ms_submitted draft.pdf

Licence: CC-BY-NC-ND 4.0

Request a copy

Share / Export

Statistics